NEJM Studies Show Promise In Malaria Regimen For Ebola Treatment, Failure Of Survivors’ Blood To Help Patients, Differences In Survival Rates Between Sexes
News outlets report on several articles looking at various Ebola treatment outcomes that were published in the New England Journal of Medicine.
Agence France-Presse: Shortage of malaria drug points to better tool vs Ebola
“…The results of a study published Wednesday in the New England Journal of Medicine show that Ebola patients given an anti-malarial drug called artesunate-amodiaquine (ASAQ) had a 31 percent lower risk of dying than those given the standard treatment for the mosquito-borne disease…” (Sheridan, 1/6).
Associated Press: Study: Ebola survivors’ blood didn’t help patients in Guinea
“…At a clinic in the capital Conakry, scientists found no difference in survival between 84 patients who got survivor blood compared to about 400 patients treated some five months earlier, according to the study published in New England Journal of Medicine…” (Cheng, 1/6).
CIDRAP News: Ebola studies pan convalescent plasma, find hope for malaria regimen
“…Both studies were published today in the latest online edition of the New England Journal of Medicine (NEJM), alongside a shorter report on gender differences during the Ebola outbreak, such as higher survival rates in female patients…” (Schnirring, 1/6).
The Guardian: Search for Ebola cure goes on as remedy based on survivors’ blood underwhelms (O’Carroll, 1/6).
New York Times: Ebola Treatment Using Plasma From Survivors Is Not Effective, Study Says (Fink, 1/6).
Reuters Health: Blood plasma from Ebola survivors fails to prevent deaths in field study (Emery, 1/6).
Science: Plasma transfusions can’t combat Ebola (Enserink, 1/6).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.